Sökning: id:"swepub:oai:DiVA.org:umu-216382" >
Post Marketing Obse...
Post Marketing Observational Study to Assess Quality of Life Changes in Swedish Patients with Moderate or Severe Hidradenitis suppurativa after 6 months on Adalimumab Treatment (HOPE study)
-
- Emtestam, Lennart (författare)
- Karolinska Institutet, Stockholm, Sweden
-
- Al-Bayatti, Ansam (författare)
- Uppsala University Hospital, Uppsala, Sweden
-
- Popovic Silwerfeldt, Karin (författare)
- Karolinska Institutet, Stockholm, Sweden
-
visa fler...
-
- Sartorius, Karin (författare)
- Karolinska Institutet, Stockholm, Sweden
-
- Shayesteh, Alexander (författare)
- Umeå universitet,Dermatologi och venereologi
-
- Linda, Weyler (författare)
- Abbvie, Sweden
-
visa färre...
-
(creator_code:org_t)
- Oxford : Wiley-Blackwell, 2019
- 2019
- Engelska.
- Relaterad länk:
-
https://eadvprogram....
-
visa fler...
-
https://urn.kb.se/re...
-
visa färre...
Abstract
Ämnesord
Stäng
- Background: Hidradenitis suppurativa (HS) has a major impact on patients’ quality of life (QoL). Numerous data indicate that blocking TNF-α results in decreased HS disease activity.Objectives: To evaluate the QoL in Swedish HS patients treated with adalimumab (ADA) in accordance with routine clinical practice (HOPE study).Methods: Data was collected from the patients’ medical records (demographics and baseline data), by investigator assessment (Hidradenitis Suppurativa Clinical Response (HiSCR)) and by patient questionnaires (DLQI and HSIA evaluating QoL; skin pain measured by NRS). Questionnaires were completed at baseline and at visits around weeks 4 (visit 2) and 12 (visit 3).Results: This descriptive interim analysis included ten patients with moderate to severe HS, 70% were women. Data was not obtained for all patients from visit 3 due to time cut-off. Median baseline DLQI score was 19 and at subsequent visits, most patients demonstrated a pronounced reduction (improvement) in DLQI. Median baseline HSIA values were 8 (item 1), 5 (item 4 and 7), respectively. At visit 2, median values had decreased to 1.5 (item 1), 0 (item 4) and 0.5 (item 7). The baseline median score of worst and average skin pain was 6.5 and 4.5, respectively. In most patients, pain scores decreased during ADA treatment. HiSCR was achieved by 70% (7/10) of patients at visit 2 and by 83% (5/6) at visit 3.Conclusion: In this study, Swedish HS patients receiving ADA in accordance with routine clinical practice demonstrated improved QoL, reduction in pain and treatment success as measured by HiSCR.
Ämnesord
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Dermatologi och venereologi (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Dermatology and Venereal Diseases (hsv//eng)
Nyckelord
- Hidradenitis suppurativa
- Quality of Life
- Adalimumab
- dermatologi och venereologi
- Dermatology and Venerology
Publikations- och innehållstyp
- vet (ämneskategori)
- kon (ämneskategori)